These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3165724)

  • 1. Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia.
    Vayuvegula B; Slater L; Meador J; Gupta S
    Cancer Chemother Pharmacol; 1988; 22(2):163-8. PubMed ID: 3165724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
    Gollapudi S; Gupta S
    Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin A and verapamil enhancement of daunorubicin-produced nucleolar protein B23 translocation in daunorubicin-resistant and -sensitive human and murine tumor cells.
    Sweet P; Chan PK; Slater LM
    Cancer Res; 1989 Feb; 49(3):677-80. PubMed ID: 2910487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil reverses the ultrastructural alterations in the plasma membrane induced by drug resistance.
    García-Segura LM; Soto F; Planells-Cases R; Gonzalez-Ros JM; Ferragut JA
    FEBS Lett; 1992 Dec; 314(3):404-8. PubMed ID: 1468576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.
    Sehested M; Skovsgaard T; van Deurs B; Winther-Nielsen H
    Br J Cancer; 1987 Dec; 56(6):747-51. PubMed ID: 3435701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.
    Slater LM; Sweet P; Stupecky M; Gupta S
    J Clin Invest; 1986 Apr; 77(4):1405-8. PubMed ID: 3457021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.
    Slater LM; Murray SL; Wetzel MW; Sweet P; Stupecky M
    Cancer Chemother Pharmacol; 1986; 16(1):50-4. PubMed ID: 3455667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclosporin A on the membrane potential and Ca2+ level of human lymphoid cell lines and mouse thymocytes.
    Vereb G; Panyi G; Balázs M; Mátyus L; Matkó J; Damjanovich S
    Biochim Biophys Acta; 1990 Aug; 1019(2):159-65. PubMed ID: 2207113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
    Boesch D; Muller K; Pourtier-Manzanedo A; Loor F
    Exp Cell Res; 1991 Sep; 196(1):26-32. PubMed ID: 1879470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.
    Larsson R; Nygren P
    Int J Cancer; 1990 Jul; 46(1):67-72. PubMed ID: 2194983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin.
    Hu XF; de Luise M; Martin TJ; Zalcberg JR
    Eur J Cancer; 1990; 26(7):814-7. PubMed ID: 2145901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446.
    Jachez B; Nordmann R; Loor F
    J Natl Cancer Inst; 1993 Mar; 85(6):478-83. PubMed ID: 8095304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
    Nygren P; Larsson R
    Int J Cancer; 1991 Jun; 48(4):598-604. PubMed ID: 2045203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
    Wang L; Kitaichi K; Hui CS; Takagi K; Takagi K; Sakai M; Yokogawa K; Miyamoto KI; Hasegawa T
    Clin Exp Pharmacol Physiol; 2000 Aug; 27(8):587-93. PubMed ID: 10901387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.